- November 22, 2026
- Updated 8:26 am
California Voters Approve Proposition 38 for Research Funding
- 25 Views
- admin
- November 10, 2026
- Health Public Health
California voters have approved Proposition 38, allowing the state to issue $8.4 billion in bonds. These funds will support immunology and immunotherapy research, focusing on curing and preventing certain chronic diseases. The Associated Press reported the measure’s approval on Monday evening.
At least $4.2 billion of the allocated funds will target research on cancer, heart disease, and Alzheimer’s disease. The measure permits California to partner with an unnamed research institute, selected by the California Department of Public Health, to receive half of the bond revenue.
Opponents of Proposition 38 argue that it places a long-term financial burden on taxpayers. They also claim that the requisites for grant qualification are stringent, leaving only the California Institute for Immunology and Immunotherapy as a suitable candidate to receive a significant portion of the funds. Gary K. Michelson, a key figure behind this proposition, co-founded the institute and was its largest supporter, investing $45 million into the campaign.
The remainder of the bond funds will be allocated for competitive research grants focusing on immunology and immunotherapy. A council comprising representatives from University of California campuses, other universities, and nonprofit research institutions will award these grants.
Supporters welcomed this decision, emphasizing the impact of federal research funding cuts on clinical trials and medical discoveries. “This victory belongs to the patients and families who have spent years fighting devastating diseases and waiting for the next medical breakthrough,” said Chris Tarver, president of the American Nurses Association\California, in a statement.
Californians face an expected annual repayment cost of $500 million to $600 million over 20 years for the bond, as estimated by the Legislative Analyst’s Office.
While there are hopes that revenue from successful research projects might offset these costs, predicting such outcomes remains uncertain.